Everything below concerns GHSR-1a. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Reported for the free peptide |
| Molecular mass | 711.85 Da | Monoisotopic value |
| Residue motif | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Non-natural residues at positions one and three |
| Primary target | GHSR-1a | Ghrelin receptor, G protein coupled |
| Reported plasma half-life | About two hours | Values vary with assay and subject group |
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Many different amphibians are neotenic, evolved to retain larval traits (such as external gills) as part of an aquatic lifestyle. For example, Ambystoma mexicanum, an extant salamander, is difficult to tell apart from the Permian temnospondyl Branchiosaurus.
17 August – SNP MSP John Mason is stripped of the party whip after a Twitter post in which he said that Israel's actions in Gaza did not amount to "genocide", something a party spokesperson describes as "completely unacceptable". 19 August – A rocket being developed by Rocket Factory Augsburg, a German company hoping to launch the UK's first space flight, explodes during a launch test at the Shetland Space Centre. The Scottish Government announces it will hold no further talks with Israeli ambassadors until there is "real progress" in resolving the Gaza conflict. Christina McKelvie, the Scottish Government's Minister for Drugs and Alcohol Policy, announces she will step back from the role while receiving treatment for secondary breast cancer. Her duties will be assumed by fellow ministers Neil Gray and Jenni Minto. 20 August – Data released by National Records of Scotland shows a 12% increase in the number of drug related deaths in Scotland during 2023, with 1,172 deaths that year, an increase of 121 from 2022. Transport Scotland announces that its pilot scheme of subsidising peak-time ScotRail fairs will end in September, having not achieved the goal of encouraging more people to travel by train rather than by road. 21 August – Aberdeen City Council announces that several hundred properties in Aberdeen affected by Reinforced Autoclaved Aerated Concrete are to be demolished and rebuilt at a cost of £150m. 22 August – Edinburgh City Council votes to introduce a tourist tax that it hopes will raise around £50m a year.
=== Breast cancer === Anastrozole is used in the treatment and prevention of breast cancer in women. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was of localized breast cancer and women received either anastrozole, the selective estrogen receptor modulator tamoxifen, or both for five years, followed by five years of follow-up. After more than 5 years the group that received anastrozole had better results than the tamoxifen group. The trial suggested that anastrozole is the preferred medical therapy for postmenopausal women with localized estrogen receptor-positive breast cancer.
Of Molecules and Men (Prometheus Books, 2004; original edition 1967) ISBN 1-59102-185-5 Life Itself: Its Origin and Nature (Simon & Schuster, 1981) ISBN 0-671-25562-2 What Mad Pursuit: A Personal View of Scientific Discovery (Basic Books reprint edition, 1990) ISBN 0-465-09138-5 The Astonishing Hypothesis: The Scientific Search for the Soul (Scribner reprint edition, 1995) ISBN 0-684-80158-2 Georg Kreisel: a Few Personal Recollections. In: Kreiseliana: About and Around Georg Kreisel (1996), pp. 25–32. ISBN 1-56881-061-X
== Medical uses == Ixazomib is used in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adults after at least one prior therapy. There are no experiences with children and youths under 18 years of age. The study relevant for approval included 722 people. In this study, ixazomib increased the median time of progression-free survival from 14.7 months (in the placebo+lenalidomide+dexamethasone study arm including 362 people) to 20.6 months (under ixazomib+lenalidomide+dexamethasone, 360 people), which was a statistically significant effect (p = 0.012). 11.7% of patients in the ixazomib group had a complete response to the treatment, versus 6.6% in the placebo group. Overall response rate (complete plus partial) was 78.3% versus 71.5%. A phase 3 study demonstrated a significant improvement in progression-free survival (PFS) with ixazomib-lenalidomide-dexamethasone (IRd) compared with placebo. High-risk cytogenetic abnormalities were defined as del(17p), t(4;14), and/or t(14;16); additionally, patients were assessed for 1q21 amplification. Of 722 randomized patients, 552 had cytogenetic results; 137 (25%) had high-risk cytogenetic abnormalities and 172 (32%) had 1q21 amplification alone. PFS was improved with IRd versus placebo in both high-risk and standard-risk cytogenetics subgroups: in high-risk patients, with median PFS of 21.4 versus 9.7 months; in standard-risk patients, with median PFS of 20.6 versus 15.6 months.
Sources: en.wikipedia.org
From 2011, new cars should have brake assist system in the EU, according to The Pedestrian Protection Regulation (EC) 78/2009. Starting in 2012, all cars under 10,000 lbs. sold in the US are required to have Electronic Stability Control. In 2014, ESP (Electronic Stability Program) and TPMS became mandatory in the European Union, with also the driver seat belt reminder and the ISOFIX system, under General Safety Regulation (EC) No 661/2009. In 2015, recognizing that safer roads are a shared responsibility, Together for Safer Roads (TSR) was formally launched to align the private sector's road safety efforts with the United Nations Decade of Action for Road Safety. In 2016 and 2017, ABS became mandatory on motorcycles in the EU. In 2018, eCall became mandatory in the EU, and reverse camera in the US. In 2019, the EU legislated to revise the General Safety Regulation (GSR), the revision includes the following automotive safety features:
Counter-Strike Online is a free-to-play spin-off available in much of eastern Asia. It was developed by Nexon, with oversight from Valve. It uses a micropayment model that is managed by a custom version of the Steam back-end. Announced in 2012 and aimed at the Asian gaming market, a sequel titled Counter-Strike Online 2 was developed by Nexon on the Source game engine and released in 2013.
== Mechanism of action == The medication, a sulfonylurea, works by binding to and inhibiting the ATP-sensitive potassium channels (KATP) inhibitory regulatory subunit sulfonylurea receptor 1 (SUR1) in pancreatic beta cells. This inhibition causes cell membrane depolarization, opening voltage-dependent calcium Channels. This results in an increase in intracellular calcium in the pancreatic beta cell and subsequent stimulation of insulin release. After a stroke, the blood–brain barrier is broken and glibenclamide can reach the central nervous system. Glibenclamide has been shown to bind more efficiently to the ischemic hemisphere. Moreover, under ischemic conditions SUR1, the regulatory subunit of the KATP- and the NCCa-ATP-channels, is expressed in neurons, astrocytes, oligodendrocytes, endothelial cells and by reactive microglia. According to the research, this and other sulphonylurea drugs also have extra hepatic effects. It works by inhibiting the enzyme Carnityl Acyl Transferase I (CAT-I) indirectly, which is present in the mitochondria. This prevents the transport of long chain fatty acids into the mitochondria for beta-oxidation. This prevents hyperglycemia for which it is prescribed.
=== 2009 === A report prepared for the British House of Lords comes to the conclusion that "The precise circumstances surrounding the August 2008 outbreak of the conflict are not yet clear but responsibility for the conflict was shared, in differing measures, by all the parties. There is evidence of a Russian military build-up prior to the August war." On 17 February 2009, the commanding General of the United States Army Europe Carter Ham commented on the training of Georgian military that the United States had trained the Georgian military for Iraq in the previous years, not for the defense of the homeland against Russia. In May 2009, anonymous European diplomat told The New York Times that NATO officials were told in April 2008 by Russia's defense chief that Georgia would be invaded later that year. In July 2009, Alexander Bastrykin, Chairman of the Investigative Committee of the Prosecutor General's Office, told journalists that the investigation of the war was almost complete. However, the guilt of Georgian president Mikheil Saakashvili in instigating the conflict in South Ossetia could not be proven. In September 2009, first president of the Czech Republic Václav Havel, Otto von Habsburg and other European politicians and thinkers wrote: "First, a big power will always find or engineer a pretext to invade a neighbour whose independence it resents. We should remember that Hitler accused the Poles of commencing hostilities in 1939, just as Stalin pinned the blame on the Finns when he invaded their country in 1940.
Sources: en.wikipedia.org
Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.
Early animal and human studies reported growth hormone release at levels that produced small changes in cortisol, prolactin and adrenocorticotropic hormone. That contrast with older secretagogues gave rise to the selectivity label. The observation is consistent across several reports but rests on a limited number of small studies.
Plasma peptidases cleave the molecule into smaller fragments, and reported half-lives in human studies are on the order of a couple of hours. The identity and activity of individual breakdown products have not been fully mapped. Questions about tissue-level clearance remain open.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.